THOUSAND OAKS, Calif. – Amgen Inc., one of the world’s largest biotechnology companies, plans to invest $200 million on a new manufacturing facility in Singapore.
The investment, spent over the next several years, will be used to fund the construction of a “world-class” manufacturing facility in Tuas Biomedical Park (TBP), reported the company, which also has a production facility in West Greenwich.
A strategic move globally, Amgen’s foreign investment places it in a position to recruit from a local pool of industry talent from nearby colleges and universities for facility positions.
“Singapore is an ideal location to further our manufacturing efforts based on its rich talent pool and friendly business environment,” Madhu Balachandran, executive vice president of operations, said in prepared remarks.
Set to begin construction within a few months, the facility’s primary function will be to expand the manufacture of monoclonal antibodies, which includes Amgen’s osteoporosis treatment Prolia, or denosumab.
TBP is Singapore’s commercial hub for biomedical giants, including GlaxoSmithKline, Lonza, Merck, Novartis, Pfizer and Roche.
PBN is now accepting applications for its newest award program and event for RI & Bristol County to celebrate the Manufacturing Renaissance that is evolving regionally and across the country. The deadline for applications is March 20th.
PBN's annual Book of Lists has been an essential resource for the local business community for almost 30 years. The Book of Lists features a wealth of company rankings from a variety of fields and industries, including banking, health care, real estate, law, hospitality, education, not-for-profits, technology and many more.